UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 3, 2004
GENTA
INCORPORATED
(Exact Name of
Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
| 0-19635 | 33-0326866 | ||
| (Commission File Number) | (IRS Employer Identification No.) | ||
| Two
Connell Drive Berkeley Heights, NJ 07922 |
07922 | ||
| (Address of Principal Executive Offices) | (Zip Code) |
(908) 286-9800
(Registrant’s
Telephone Number, Including Area Code)
(Former Name or
Former Address, if Changed Since Last Report)
Item 5. Other Events and Regulation FD Disclosure.
On
May 3, 2004, Genta Incorporated (“Genta”) issued a press release
announcing that Genta and Aventis presented results of their Phase 3 trial of
Genasense ™ (oblimersen sodium) Injection in combination with dacarbazine
(DTIC) versus DTIC alone at the Oncologic Drugs Advisory Committee (ODAC) of the U.S.
Food and Drug Administration (FDA). The press release is attached hereto as Exhibit 99.1
and incorporated herein by reference.
| Exhibit Number |
Description | |
|
|
|
|
| 99.1 | Press Release dated May 3, 2004 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| GENTA INCORPORATED | ||||
| Date: | May 3, 2004 | By: | /s/ William P. Keane | |
| |
|
|||
| Name: |
William P. Keane | |||
| Title: | Vice President, Chief Financial Officer and Corporate Secretary | |||
EXHIBIT INDEX
| Exhibit Number |
Description |
Sequentially Numbered Page |
|
| 99.1 | Press Release dated May 3, 2004 |